Welcome to Scribd. Sign in or start your free trial to enjoy unlimited e-books, audiobooks & documents.Find out more
Download
Standard view
Full view
of .
Look up keyword
Like this
66Activity
0 of .
Results for:
No results containing your search query
P. 1
amlodipine

amlodipine

Ratings:

5.0

(1)
|Views: 6,045|Likes:
Published by api-3797941

More info:

Published by: api-3797941 on Oct 17, 2008
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as DOC, PDF, TXT or read online from Scribd
See more
See less

03/18/2014

pdf

text

original

amlodipine
(amlo e' di peen)
Norvasc
Pregnancy Category C
Drug classes

Calcium channel-blocker
Antianginal drug
Antihypertensive

Therapeutic actions

Inhibits the movement of calcium ions across the membranes of cardiac and arterial
muscle cells; inhibits transmembrane calcium flow, which results in the depression of
impulse formation in specialized cardiac pacemaker cells, slowing of the velocity of
conduction of the cardiac impulse, depression of myocardial contractility, and dilation of
coronary arteries and arterioles and peripheral arterioles; these effects lead to decreased
cardiac work, decreased cardiac oxygen consumption, and in patients with vasospastic
(Prinzmetal's) angina, increased delivery of oxygen to cardiac cells.

Indications
\u2022
Angina pectoris due to coronary artery spasm (Prinzmetal's variant angina)
\u2022
Chronic stable angina, alone or in combination with other agents
\u2022
Essential hypertension, alone or in combination with other antihypertensives
Contraindications and cautions
\u2022
Contraindicated with allergy to amlodipine, impaired hepatic or renal function,
sick sinus syndrome, heart block (second or third degree), lactation.
\u2022
Use cautiously with CHF, pregnancy.
Available forms
Tablets\u20142.5, 5, 10 mg
Dosages
ADULTS
Initially, 5 mg PO daily; dosage may be gradually increased over 10\u201314 days to a
maximum dose of 10 mg PO daily.
PEDIATRIC PATIENTS
Safety and efficacy not established.
GERIATRIC PATIENTS OR PATIENTS WITH HEPATIC IMPAIRMENT
Initially, 2.5 mg PO daily; dosage may be gradually adjusted over 7\u201314 days based on
clinical assessment.
Pharmacokinetics
Route
Onset
Peak
Oral
Unknown
6\u201312 hr

Activity (66)

You've already reviewed this. Edit your review.
1 hundred reads
1 thousand reads
Chelsea Manry liked this
Camille Üü liked this
Haley Bell liked this
Jam Mendoza liked this
Melissa Hegarty liked this
akkinata liked this

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->